Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.53 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11665739 | 0.90 | SLC6A2 (0.54) | AKR1C3AKR1C1POLBATMSLC6A3 | |
| SCHEMBL3543298 | 0.89 | AKR1C3 (0.69) | AKR1C3AKR1C1POLBATMSLC6A3 | |
| SCHEMBL24434987 | 0.89 | AKR1C3 (0.69) | AKR1C3AKR1C1POLBATMSLC6A3 | |
| SCHEMBL28625883 | 0.85 | AKR1C3 (0.78) | AKR1C3AKR1C1POLBATMSLC6A3 | |
| SCHEMBL26491020 | 0.85 | AKR1C3 (0.61) | AKR1C3AKR1C1ATMMEN1KMT2A | |
| SCHEMBL343144 | 0.84 | CHRNB2 (0.47) | AKR1C3AKR1C1POLBATMSLC6A3 | |
| SCHEMBL343145 | 0.84 | CHRNB2 (0.47) | AKR1C3AKR1C1POLBATMSLC6A3 | |
| SCHEMBL343146 | 0.84 | CHRNB2 (0.47) | AKR1C3AKR1C1POLBATMSLC6A3 | |
| SCHEMBL21513698 | 0.84 | LATS1 (0.46) | KMT2AALDH1A1 | |
| SCHEMBL3540595 | 0.84 | AKR1C3 (0.56) | AKR1C3AKR1C1POLBSLC6A3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3102198-B1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10059667-B2 | Antidiabetic compounds | MERCK SHARP & DOHME CORP. (US) | 2018-08-28 | — | — | US | disclosed |
| EP-3102198-A1 | ANTIDIABETIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-11-17 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9120779-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2015-09-01 | — | — | US | disclosed |
| WO-2015119899-A1 | ANTIDIABETIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2015-08-13 | — | — | WO | disclosed |
| CN-102300462-B | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS INC | 2015-01-28 | — | — | CN | disclosed |
| EP-2774927-A1 | Inhibitors of HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2014-09-10 | — | — | EP | disclosed |
| CN-102300462-A | Inhibitors Of Hcv Ns5a | — | 2011-12-28 | — | — | CN | disclosed |
| EP-2373168-A1 | INHIBITORS OF HCV NS5A | Presidio Pharmaceuticals, Inc. (US) | 2011-10-12 | — | — | EP | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2011-09-29 | — | — | US | disclosed |
| WO-2010065681-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
| US-4109015-A | PROSTAGLANDINS, LUTEOLYTIC | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332968-A1 | ANTIDIABETIC COMPOUNDS | GPR119, GLP1R, GIPR | AKR1C3 1594/4885AKR1C1 1568/4885POLB 4817/4885 |
| US-10059667-B2 | Antidiabetic compounds | GPR119, GLP1R, GIPR | AKR1C3 1594/4885AKR1C1 1568/4885POLB 4817/4885 |
| US-20110237579-A1 | INHIBITORS OF HCV NS5A | MAVS, HAVCR2, EIF2AK2 | AKR1C3 4411/4885AKR1C1 4453/4885POLB 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.